"Alzheimer's Theory That's Been Drug Graveyard Facing Test"
BACE is an enzyme that works like scissors to release the sticky amyloid and create the characteristic plaques that build up in the brains of Alzheimer’s patients. Merck announced this week that it will start approval studies of its BACE inhibitor. “The rationale for this drug is about as good as it gets,” said Samuel Gandy, MD, Mount Sinai Professor in Alzheimer’s Research, Professor of Neurology, Psychiatry, and Associate Director of the Alzheimer’s Disease Research Center at the Icahn School of Medicine at Mount Sinai. “In the lab, BACE inhibitors have been among the most potent compounds for reducing the production of amyloid, thereby preventing formation of the nerve-cell-killing form.” Learn more
Scientists Develop Novel Approach to Enhance Drug Delivery for Brain Tumors in Children
Mar 02, 2023 View All Press Releases
Researchers Identify the Role of an Alzheimer’s Disease Risk Gene in the Brain
Nov 30, 2022 View All Press Releases
